IL319866A - Ligand-drug conjugate of exatecan analogue, and medical use thereof - Google Patents
Ligand-drug conjugate of exatecan analogue, and medical use thereofInfo
- Publication number
- IL319866A IL319866A IL319866A IL31986625A IL319866A IL 319866 A IL319866 A IL 319866A IL 319866 A IL319866 A IL 319866A IL 31986625 A IL31986625 A IL 31986625A IL 319866 A IL319866 A IL 319866A
- Authority
- IL
- Israel
- Prior art keywords
- exatecan
- analogue
- ligand
- drug conjugate
- medical use
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022123665 | 2022-09-30 | ||
| PCT/CN2023/122616 WO2024067811A1 (en) | 2022-09-30 | 2023-09-28 | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319866A true IL319866A (en) | 2025-05-01 |
Family
ID=90476247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319866A IL319866A (en) | 2022-09-30 | 2023-09-28 | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250295798A1 (en) |
| EP (1) | EP4594327A1 (en) |
| JP (1) | JP2025534324A (en) |
| KR (1) | KR20250069963A (en) |
| CN (1) | CN119948031A (en) |
| AU (1) | AU2023349279A1 (en) |
| CL (1) | CL2025000947A1 (en) |
| CO (1) | CO2025005067A2 (en) |
| IL (1) | IL319866A (en) |
| MX (1) | MX2025003727A (en) |
| WO (1) | WO2024067811A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CN120731208A (en) | 2022-12-16 | 2025-09-30 | 杭州百凯生物医药有限公司 | Novel camptothecin derivatives and their conjugates |
| WO2024158996A2 (en) * | 2023-01-25 | 2024-08-02 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2024227432A1 (en) * | 2023-04-30 | 2024-11-07 | 泰诚思(上海)生物医药有限公司 | Camptothecin derivative, method for preparing same and use thereof, antibody-drug conjugate, and use thereof |
| WO2025048588A1 (en) * | 2023-08-31 | 2025-03-06 | 주식회사 피노바이오 | Novel camptothecin derivative and carrier-drug conjugate comprising same |
| WO2025222052A2 (en) * | 2024-04-18 | 2025-10-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| CN122497675A (en) * | 2024-06-05 | 2026-07-31 | 荣昌生物制药(烟台)股份有限公司 | Camptothecins compound and application thereof |
| WO2026012411A1 (en) * | 2024-07-11 | 2026-01-15 | 上海华奥泰生物药业股份有限公司 | Exatecan derivative and use thereof |
| WO2026016997A1 (en) * | 2024-07-15 | 2026-01-22 | 杭州中美华东制药有限公司 | Camptothecin compound and use thereof |
| WO2026021476A1 (en) | 2024-07-24 | 2026-01-29 | Beone Guangzhou Biologics Manufacturing Co., Ltd. | Anti-cmet and anti-egfr multispecific antibody drug conjugates |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3359955B2 (en) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | Antitumor agent |
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| TWI871999B (en) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | Anti-her3 antibody drug conjugate |
| UA130338C2 (en) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, METHOD FOR ITS PREPARATION AND ITS USE |
| CN111689980A (en) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | Camptothecin drug and antibody conjugate thereof |
| CN112125915A (en) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | A kind of camptothecin derivative and its conjugate |
| BR112022024930A2 (en) * | 2020-06-08 | 2022-12-27 | Baili Bio Chengdu Pharmaceutical Co Ltd | CAMPTOTHECIN DRUG HAVING HIGH STABILITY HYDROPHILIC CONNECTION UNIT AND CONJUGATE THEREOF |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| NZ781239A (en) * | 2020-09-15 | 2024-11-29 | Systimmune Inc | A camptothecin drug and its antibody conjugate thereof |
| DK4516357T3 (en) * | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | ANTITUMORMORE COMPOUND, METHOD FOR PREPARING THEREOF AND USE THEREOF |
| EP4227310A4 (en) * | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| AU2022216696A1 (en) * | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| AU2022269073A1 (en) | 2021-05-07 | 2023-11-23 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CA3224492A1 (en) * | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CN115850291B (en) * | 2021-09-24 | 2024-11-15 | 石药集团巨石生物制药有限公司 | Camptothecin derivatives and uses thereof |
| TW202344252A (en) * | 2022-05-09 | 2023-11-16 | 大陸商同宜醫藥(蘇州)有限公司 | Camptothecin derivative, antibody-drug conjugate and pharmaceutical composition based on same, and use thereof |
-
2023
- 2023-09-28 AU AU2023349279A patent/AU2023349279A1/en active Pending
- 2023-09-28 KR KR1020257013826A patent/KR20250069963A/en active Pending
- 2023-09-28 IL IL319866A patent/IL319866A/en unknown
- 2023-09-28 EP EP23871036.2A patent/EP4594327A1/en active Pending
- 2023-09-28 JP JP2025518289A patent/JP2025534324A/en active Pending
- 2023-09-28 CN CN202380068225.8A patent/CN119948031A/en active Pending
- 2023-09-28 WO PCT/CN2023/122616 patent/WO2024067811A1/en not_active Ceased
-
2025
- 2025-03-25 US US19/089,217 patent/US20250295798A1/en active Pending
- 2025-03-27 MX MX2025003727A patent/MX2025003727A/en unknown
- 2025-03-28 CL CL2025000947A patent/CL2025000947A1/en unknown
- 2025-04-23 CO CONC2025/0005067A patent/CO2025005067A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250295798A1 (en) | 2025-09-25 |
| MX2025003727A (en) | 2025-05-02 |
| KR20250069963A (en) | 2025-05-20 |
| CN119948031A (en) | 2025-05-06 |
| CO2025005067A2 (en) | 2025-05-19 |
| JP2025534324A (en) | 2025-10-15 |
| AU2023349279A1 (en) | 2025-05-15 |
| EP4594327A1 (en) | 2025-08-06 |
| WO2024067811A1 (en) | 2024-04-04 |
| CL2025000947A1 (en) | 2025-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202211870B (en) | Imidazolidinone derivatives and medical use thereof | |
| EP4112050A4 (en) | Use of nucleoside compound in treatment of coronavirus infectious diseases | |
| EP4130006A4 (en) | ANTI-PSMA ANTIBODY EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | |
| IL318543A (en) | Fibroblast activation protein-targeted compositions and methods of use thereof | |
| CA3248290A1 (en) | Disposable controls, re-usable devices, and their methods of use | |
| IL316049A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| GB202306325D0 (en) | Antibody-drug conjugate compounds, and methods of use and treatment | |
| EP4216961A4 (en) | Compositions and methods for treatment of coronavirus infection | |
| EP4138852A4 (en) | Compositions and methods for the treatment of pain | |
| IL314781A (en) | Thienopyrrolotriazine compounds, their preparation and their therapeutic use | |
| CA3269231A1 (en) | Ligand-drug conjugate of exatecan analogue, and medical use thereof | |
| IL327395A (en) | Use of alvelestat in specific patients | |
| AU2021344801A9 (en) | Specific cardiac tissue and the use thereof in the treatment of cardiac pathologies | |
| MX2022016148A (en) | Formulations. | |
| IL326074A (en) | Fibroblast activation protein-targeted compositions and methods of use thereof | |
| GB202306474D0 (en) | Seed treatment composition and use | |
| IL316558A (en) | New medical use of tafoxiparin | |
| IL318364A (en) | Therapeutic compounds, formulations, and use thereof | |
| EP3826531A4 (en) | Wireless medical implants and methods of use | |
| GB202008250D0 (en) | Diagnosis, prevention and treatment of coronavirus infection | |
| HK40108890A (en) | Use of antibody-drug conjugate, and combined drug and use thereof | |
| HK40096914A (en) | Antibody-drug conjugate and medical use thereof | |
| CA3280839A1 (en) | Antibody-drug conjugate compounds, and methods of use and treatment | |
| CA220512S (en) | Medical tissue clip | |
| CA3305988A1 (en) | Use of alvelestat in specific patients |